공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

네프릴리신 : 파이프라인 리뷰

Neprilysin - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 359835
페이지 정보 영문 74 Pages
가격
US $ 3,500 ₩ 3,873,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,746,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,619,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


네프릴리신 : 파이프라인 리뷰 Neprilysin - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 74 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

네프릴리신(Neprilysin)을 표적으로 하는 약제의 적응증, 개발 단계, 작용기서, 투여 경로 및 분자 종류별 분석, 약제의 약리 작용에 관한 설명, 지금까지의 연구 개발 동향, 최신 뉴스와 발표, 약제 개발에 참여하고 있는 주요 기업 개요, 휴지/중지된 프로젝트 정보 등을 전해드립니다.

서론

  • 조사 범위

네프릴리신 개요

치료제 개발

네프릴리신 : 개발중인 제품 - 개발 단계별

네프릴리신 : 개발중인 제품 - 치료 범위별

네프릴리신 : 개발중인 제품 - 적응증별

네프릴리신 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

네프릴리신 : 기업에서 개발중인 제품

네프릴리신 : 치료제 평가

  • 단독요법/병용 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

네프릴리신 치료제 개발에 참여하고 있는 기업

  • Novartis AG
  • Pharmaleads SA
  • Theravance Biopharma, Inc.

약제 개요

네프릴리신 : 휴지중인 프로젝트

네프릴리신 : 개발이 중지된 제품

네프릴리신 : 주요 뉴스와 프레스 릴리스

부록

KSM 16.06.27

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Novartis AG, H2 2019
  • Pipeline by Pharmaleads SA, H2 2019
  • Pipeline by Stragen New Molecules, H2 2019
  • Pipeline by Theravance Biopharma Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Neprilysin - Pipeline Review, H2 2019, outlays comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Neprilysin also known as membrane metallo-endopeptidase (MME) is an enzyme that is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P and bradykinin. It degrades the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been a cause of Alzheimer's disease. Inhibition of neprilysin helps in treatment of Pain and hypertension. The molecules developed by companies in Pre-Registration, Phase I and Preclinical stages are 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Ophthalmology which include indications Chronic Heart Failure, Hypertension, Acute Heart Failure, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Alzheimer's Disease, Cancer Pain, Diastolic Heart Failure, Hypertrophic Cardiomyopathy, Keratoconjunctivitis Sicca (Dry Eye), Neuropathic Pain (Neuralgia), Ocular Pain (Eye Pain), Pain, Post-Myocardial Infarction, Post-Operative Pain, Systolic Heart Failure and Traumatic Pain.

Furthermore, this report also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
  • The report reviews Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Overview
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Companies Involved in Therapeutics Development
  • Novartis AG
  • Pharmaleads SA
  • Stragen New Molecules
  • Theravance Biopharma Inc
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Drug Profiles
  • (sacubitril + valsartan) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-265 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-37 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate Neprilysin for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STR-324 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TD-0212 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TD-0714 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TD-1439 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Dormant Products
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Discontinued Products
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 18, 2019: Promising results for Novartis's Entresto in HFpEF sub-populations
  • Oct 01, 2019: Novartis entresto receives FDA approval for pediatric heart failure, helping to address critical unmet need for treatment options
  • Sep 02, 2019: Novartis's heart failure drug Entresto presents mixed trial results
  • Sep 01, 2019: Novartis PARAGON-HF trial suggests Entresto benefit in HFpEF patients but narrowly misses primary endpoint
  • Aug 19, 2019: Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
  • Jul 29, 2019: PARAGON-HF study by Novartis misses primary goal
  • Jul 22, 2019: Critical heart drug too pricey for some Medicare patients
  • Mar 18, 2019: Compound improves heart failure biomarker even after hospitalization
  • Mar 16, 2019: Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
  • Mar 14, 2019: Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
  • Dec 03, 2018: Novartis announces new data that shows Entresto (sacubitril/valsartan) can be initiated both pre- or post-discharge with comparable safety and tolerability in patients with heart failure
  • Nov 21, 2018: Novartis heart failure treatment Entresto is awarded prestigious Prix Galien Canada innovative product award
  • Nov 13, 2018: Novartis reports positive results from PIONEER-HF trial
  • Nov 05, 2018: Novartis provides update on Entresto
  • Aug 25, 2018: Novartis announces new data that show Entresto (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q